LNA Santé Expands French Nursing Home Portfolio with Multi-Facility Acquisition

LNA Santé is expanding its French footprint by acquiring five nursing homes (EPHADs) totaling 539 beds across the Rhône, Loire, and Bouches-du-Rhône regions. The company also acquired a 77-bed operating license for the Claude Debussy EPHAD from Clariane, aiming to increase its total capacity by approximately 5%.

Which facilities did LNA Santé acquire?

The acquisition includes five EPHADs distributed across three French departments: Rhône, Loire, and Bouches-du-Rhône, totaling 539 beds. According to reports from Zonebourse, LNA Santé also secured an operating authorization from the Clariane group for the Claude Debussy EPHAD. This specific facility, which has 77 beds, had been closed since November 2023.

What is the expected financial impact of the deal?

Analysts at Kepler Cheuvreux estimate these acquisitions will generate roughly 25 million euros in annual revenue. This figure represents approximately 7% to 8% of LNA Santé’s total EPHAD revenues in France and about 3% of the group’s overall turnover. While the transaction focuses exclusively on the purchase of business assets (fonds de commerce), Kepler Cheuvreux notes that the operation will likely be slightly dilutive for operating margins initially, with profitability improving as the group integrates the sites.

How does this fit into LNA Santé’s long-term strategy?

LNA Santé uses a specific integration model centered on operational turnaround, renovation, and increasing occupancy rates. According to Kepler Cheuvreux, this process typically spans two to three years. Oddo BHF analysts noted that the acquired establishments will likely require restructuring or complete rebuilding to meet company standards, a process expected to take several years.

Oddo BHF characterized this move as one of the group’s most significant acquisitions since the Clinique Développement deal in 2020. The analysts stated the expansion highlights the company’s financial discipline and the resilience of its business model.

What are the analyst projections for LNA Santé stock?

Market analysts have responded positively to the news, though their price targets differ:

• Kepler Cheuvreux: Maintains a “Buy” rating with a price target of 42 euros.
• Oddo BHF: Maintains a “Neutral” rating but raised its price target from 28 to 36 euros.

The stock reacted favorably to the announcement, trading up 2.27% at 36 euros on the Paris Stock Exchange, per Zonebourse data.

Comparison of Analyst Outlooks